Immusoft is the brainchild of Matthew Scholz, who conceived an idea for fighting disease by modifying information in human immune cells. Matthew successfully recruited a multi-disciplinary core team with substantial clinical and research experience to transform his vision into proof of concept. That team, guided by key advisors who are top experts in cell therapy, gene therapy, virology and regulatory oversight, is rapidly moving Immusoft from proof of concept to clinical trials.
Mr. Scholz is the founder and CEO of Immusoft. With Immusoft as his third venture, Matthew has 12 years of experience connecting real-world needs with cutting-edge technical solutions. Prior projects include mobile application development and GPS-based fleet logistics (a start-up that he sold in 2009). He holds a degree in computer science from the University of Washington. See full bio here.
Dr. Herbig holds a Ph.D. in molecular biology as well as an M.B.A. from the University of Washington. His research has covered a wide breadth of topics and approaches, focusing on the development of technology platforms, addressing unmet needs. Dr. Herbig’s rich experience with protein biochemistry, genetics, and cellular biology, provides a well-rounded perspective from which to guide the development and implementation of ISP™ technologies. Dr. Herbig has been with Immusoft since late 2009 and continues to improve the ISP™ platform by pioneering new innovations in B cell manipulation and gene delivery. See full bio here.
Dr. McIvor has been actively working in gene therapy since the birth of the field, starting with some of the earliest work on gene transfer into animal tissues in vivo at Genetech in the mid 1980s. He served as Director of the Gene Therapy Program at University of Minnesota’s Institute of Human Genetics. He is a two-time former member of the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) has served extensively on NIH study sections and the Scientific Advisory Board of the NIH National Gene Vector Laboratories. Dr. McIvor is also currently a member of the Gene Therapy Resource Program Steering Committee for the NHLBI, and serves on the Editorial Board for Molecular Therapy. He has extensive experience in human gene therapy, developing both viral and non-viral vectors for the treatment of genetic diseases and cancer. See full bio here.
Director of Operations: John Z. Hall
Mr. Hall is a serial entrepreneur with interests in cancer diagnostics, materials science, and microscopy. He earned a B.S. in Neuroscience and minor in Chemistry from the University of California, Santa Cruz in 2003 where he was a research assistant at the Santa Cruz Institute of Particle Physics Retina Group, a neuro-biophysics group studying the eye. He attended the UC Berkeley Haas School of Business BioExec Institute Series in 2008, completed Stanford's Advanced Project Management course in 2010, and the Nanoscience Program from Foothill College in 2012. This is Mr. Hall's third biomedical start-up. See full bio here.
Director of Research: Mei Xu, Ph.D.
Dr. Xu has a broad academic and research background in medicine, epidemiology, statistics and molecular and cellular biology. She has specific training and expertise performing a wide range of biological assays and research. At Immusoft she oversees the daily execution of most cell culture duties, performs data analysis and provides guidance into experimental design. See full bio here.